GlobeNewsWire
21 Sept 2025, 12:39 UTC · 51w ago
Verdict
Headline takes no side. We score ALT −1.00 across three claims.
Our read: bearish.
ALT score
−1.00
More negative than 95% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
3 claims · scored −1 bearish … +1 bullish
Altimmune's IMPACT Phase 2b MASH trial of Pemvidutide failed to achieve statistical significance in its fibrosis reduction primary endpoint.
So whatFailure to meet a primary clinical endpoint for a key drug candidate is a major catalyst for devaluation in biotech companies.
More negative than 98% of claims this week
A federal securities class action lawsuit has been filed against Altimmune alleging that the company provided inflated expectations prior to the trial results.
Continue reading
5 related stories
Search tags
More negative than 80% of claims this week
Altimmune's common stock price dropped 53.2% in a single day following the announcement of the trial results.
More negative than 66% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit following a 53.2% stock price drop due to failed statistical significance in a clinical trial.
More negative than 78% of ticker scores this week
Mentioned in the context of a law firm soliciting investors who suffered losses, implying potential legal claims.
More negative than 78% of ticker scores this week
Mentioned in the context of a law firm soliciting investors who suffered losses, implying potential legal claims.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
2h ago
Price reaction
Expected −1.00Actual −13.5%
Price agrees with the score
245 sessions since publication. $3.27 vs $3.78 close before publication (Sep 19). Not market-adjusted.
ALT chart →
